Last reviewed · How we verify

Duac™Once Daily Gel

GlaxoSmithKline · Phase 3 active Small molecule

Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease inflammation in acne lesions.

Duac combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and decrease inflammation in acne lesions. Used for Acne vulgaris.

At a glance

Generic nameDuac™Once Daily Gel
SponsorGlaxoSmithKline
Drug classTopical antibiotic combination
TargetBacterial 50S ribosome (clindamycin); non-specific oxidative antimicrobial (benzoyl peroxide)
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Propionibacterium acnes. Benzoyl peroxide generates reactive oxygen species that have broad antimicrobial activity and also help reduce sebum production and comedone formation. The combination provides synergistic antibacterial and anti-inflammatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: